Fed. Circ.'s Approach To Unexpected Results In Pharma Cases

There have been many obviousness challenges to pharmaceutical patents since the generic industry began contesting the validity of patents protecting brand company products under the Hatch-Waxman framework. In many, patentees have...

Already a subscriber? Click here to view full article